NextCure, Inc.
9000 Virginia Manor Rd. Suite 200
Beltsville
MD
20705
United States
Tel: (240)399-4900
Website: https://www.nextcure.com/
Email: Info@NextCure.com
Business Spotlight - Nextcure
98 articles about NextCure, Inc.
-
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting
11/3/2022
NextCure, Inc. (Nasdaq: NXTC) today announced that clinical trial investigator Nicholas Short, M.D., Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, will present a Trials in Progress poster for NC525, a novel first-in-class immunomedicine, at the American Society of Hematology (ASH) annual meeting in New Orleans.
-
NextCure Provides Update and Reports Third Quarter 2022 Financial Results
11/3/2022
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update and reported third quarter 2022 financial results.
-
NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board
10/27/2022
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced the appointment of Lisa M. Coussens, PhD, FAACR, to its Scientific Advisory Board.
-
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
10/5/2022
NextCure, Inc. today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Boston in November 8-12, 2022.
-
NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors
10/4/2022
NextCure, Inc. today announced the initiation of a Phase 1b/2 clinical trial to evaluate NC410 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with immune checkpoint refractory or immune checkpoint naïve solid tumors.
-
NextCure to Present at the Ladenburg Thalmann Healthcare Conference
9/22/2022
NextCure, Inc. (Nasdaq: NXTC today announced that it will present at the Ladenburg Thalmann Healthcare Conference in New York City on Thursday, September 29th at 10 am ET.
-
NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results
8/4/2022
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, reported second quarter 2022 financial results and provided a business update.
-
NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation
7/6/2022
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a paper titled “Development of an Immunohistochemical Assay for Siglec-15” in Laboratory Investigation.
-
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM
6/27/2022
NextCure, Inc. presented in vivo data at the 2022 ECM Pharmacology Congress in Copenhagen that demonstrated NC410 remodels tumor ECM, enhances immune cell infiltration, alleviates immunosuppression, and reduces tumor growth in a humanized mouse tumor model.
-
NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting
6/22/2022
NextCure, Inc. announced that collaborator Brahm Segal, M.D., of Roswell Park Comprehensive Cancer Center shared nonclinical data from a research study that models the ability of NC410 to block neutrophil-mediated suppression of T cells in a tumor microenvironment at the 24th Translational Research Cancer Centers Consortium Annual Meeting.
-
NextCure to Present at the JMP Securities Life Sciences Conference in June 2022
6/8/2022
NextCure, Inc. announced that it will participate in a fireside chat at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 15th at 2 pm ET.
-
NextCure Provides Business Update and Reports First Quarter 2022 Financial Results
5/5/2022
NextCure, Inc. reported first quarter 2022 financial results and provided a business update.
-
NextCure to Present at the BofA Securities 2022 Healthcare Conference
5/3/2022
NextCure, Inc. today announced that it will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference in Las Vegas on Tuesday May 10th at 10:40 am PT.
-
NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation
4/19/2022
NextCure, Inc. announced the publication of a paper titled “Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication” in the Journal of Clinical Investigation.
-
NextCure to Present at 21st Annual Needham Virtual Healthcare Conference
4/5/2022
NextCure, Inc. announced that it will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12th at 3 pm ET.
-
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
3/3/2022
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2021 financial results and provided a business update.
-
NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference
2/8/2022
NextCure, Inc. announced that it will present at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday February 16th at 10:40 am ET.
-
NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting
12/13/2021
NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced new data in oral and poster presentations at the American Society of Hematology annual meeting in Atlanta, Georgia, and on a virtual platform.
-
NextCure to Present at The JMP Securities Hematology and Oncology Summit
11/30/2021
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit.
-
NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
11/22/2021
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in the Piper Sandler Virtual 32nd Annual Healthcare Conference on November 30th.